Skip to main content
Tulane Home Tulane Home

Prostate Clinical Trials

PDL-1 Inhibition With Avelumab and Concurrent Second-Generation ADT in African Americans With Castrate-Resistant Metastatic Prostate Cancer
More Information

Constellation CPI 1205
A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
More Information

A Phase 1B Trial of Radium-223 and Niraparib in Patients With Castration Resistant Prostate Cancer (NiraRad)
More Information

BAY 16996
A Phase 4 Long-Term Follow-Up Study to Define the Safety Profile of Radium-223 Dichloride
More Information

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
More Information

A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration Resistant Prostate Cancer and DNA Repair Anomalies
More Information

Comprehensive Genetic Characterization of Intraprostatic Chronic Inflammation and Prostate Cancer in
African American Men

TUHC 07/25/13 - Genetics of Prostate Cancer

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)
More Information

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer (PANTHER)
More Information

Phase 1/2 Open-Label, Multi-Center, Dose-Escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-Ligand Therapy in Patients with Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-Resistant Prostate Cancer, Following Previous Systemic Treatment
More Information

Merck 010
A Phase 3, Randomized Open-Label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-Generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
More Information

Merck 641
A Phase 3, Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
More Information